Gastric Cancer Forecast and Market Analysis to 2024

Gastric Cancer Forecast and Market Analysis to 2024

  • December 2017 •
  • 334 pages •
  • Report ID: 5336362 •
  • Format: PDF
Disease Overview
Gastric cancer is the second-leading cause of cancer-related mortality worldwide. There is significant geographic variation in the burden of the disease: incidence and mortality are notably high in East Asia, China, Eastern Europe, and Latin America, whereas the disease is no longer as common in North America and Western Europe.

Globally, there has been a steady decline in incidence over the past 50 years. This is mostly attributable to the decline in prevalence of H. pylori infections, a decline in tobacco use, and improvements in food preservation and diet.

Market Snapshot
The gastric cancer market is projected to reach $2.1bn in value by 2026, with growth driven by immunotherapies.
Cyramza plays an important role in the second-line treatment of metastatic and distant relapse gastric cancer.
Despite declining incidence proportions, the number of cases is forecasted to increase and prognosis remains poor.
Cyramza’s dominance in second-line advanced gastric cancer is being challenged as immunotherapies enter the market.
Bavencio will target the maintenance setting in order to avoid direct competition with established immunotherapies.
Access restrictions are moderate in gastric cancer and GIST.